Watchers of the percolating myasthenia gravis space are waiting eagerly for data from Dianthus Therapeutics Inc.’s phase II Magic study testing DNTH-103, an active C1s inhibitor, compared to placebo ...

Research presented at the recent annual meeting of the Academy of Managed Care Pharmacy highlights outcomes among patients ...

The U.S. Food and Drug Administration has approved a self-injection version of Vyvgart Hytrulo (efgartigimod alfa and ...

Marla Black Morgan, MD, with Phoebe Neurology Associates, presented findings on a study into the diagnostic journey of ...

Dr Nicholas Silvestri reports that the 2025 AAN meeting highlighted significant advances in myasthenia gravis, including ...

The FDA has approved a subcutaneous self-injectable for adults with generalized myasthenia gravis who are anti-acetylcholine ...

There is no guarantee that they will become commercially available for the use(s) under investigation. * Myasthenia Gravis Foundation of America (MGFA) Class II-IV gMG and likely not in need v of a ...

Carte­sian Ther­a­peu­tics said its au­tol­o­gous CAR-T ther­a­py has shown “sus­tained ben­e­fits” in peo­ple with a rare au­toim­mune dis­ease, ac­cord­ing to the lat­est ...

Interim results from the ME&MGopen study demonstrate strong adherence, high usability, and meaningful clinical associations in myasthenia gravis The ME&MGopenTM study highlights the potential ...

Participants treated with Descartes-08 were observed to have an average Quantitative Myasthenia Gravis Score (QMG) reduction of 4.8 (±1.7) points at month 4, which deepened through month 12 (6.0 ...

Descartes-08 represents a flagship advancement in Cartesian’s mission to transform the treatment landscape for autoimmune diseases, with this latest data reinforcing its potential as a safe and ...